Genelux (GNLX) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed Genelux (GNLX) over the past year, gaining 4.9% versus a loss of 47.4%. Genelux is the larger company by market cap ($115.8 million vs $114.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | PMVP |
|---|---|---|
| Share price | $2.56 | $1.52 |
| Market cap | $115.83M | $114.78M |
| 1-day change | +2.40% | +2.01% |
| YTD return | -42.66% | +19.20% |
| 1-year return | -47.37% | +4.93% |
| 5-year return | — | -93.78% |
| EPS (TTM) | $-0.86 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.54 | $1.91 |
| 52-week low | $2.29 | $1.02 |
| Distance from 52-week high | -70.01% | -20.42% |
| Analyst consensus | none | none |
| Avg. price target upside | +635.55% | +176.32% |
| Average volume | 276.16K | 661.39K |
| Shares outstanding | 45.25M | 75.51M |
| Employees | 25 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed GNLX by 52.3 percentage points over the past year.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
GNLX vs PMVP FAQ
Which is bigger, Genelux or PMV Pharmaceuticals?
Genelux (GNLX) is larger, with a market capitalization of $115.83M compared with $114.78M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, GNLX or PMVP?
PMVP returned +4.93% over the past 12 months, compared with -47.37% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.